Where do Anti-TROP2 ADCs Factor into Advanced TNBC Care?
Offered By: The University of Chicago via Independent
Course Description
Overview
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series focused on TNBC. This multidisciplinary tumor board discusses a patient with advanced TNBC and how novel anti-TROP2 antibody drug conjugates (ADCs) therapy may play a role.
Educational Partner: The Academy for Continued Healthcare Learning (ACHL)
Medium: Online Presentation
Commercial Support: Support for this activity has been provided through educational grants from Gilead Sciences Inc.
Sponsored by the University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Syllabus
At the conclusion of this activity, participants will be able to:
- Discuss new targeted treatment approaches in the setting of TNBC;
- Discuss the role of ADC therapies and TROP2 for triple-negative breast cancer.
Tags
Related Courses
An Evidence-Based Approach to the Diagnosis and Management of Migraines in Adults in the Primary Care and General Neurology SettingStanford University via edX To Prescribe or Not To Prescribe? Antibiotics and Outpatient Infections
Stanford University via edX Free of Pain #1 - release back originated pains by yourself
Udemy The Clinical Picture of Celiac Disease and How to Make the Diagnosis
Columbia University via Independent How Common is Celiac Disease Around the World? Role of Gluten Timing and Quantity, and Environmental Risk Factors
Columbia University via Independent